Naïla Aba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Naïla Aba has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Brice Fresneau
Department of Children and Adolescents Oncology, Gustave Roussy, Villejuif, France
20 shared publications - Nadia Haddy
EPI-PHARE, Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products, and French National Health Insurance), Saint-Denis Cedex, France
20 shared publications - Claire Ducos
Radiation Epidemiology Team, Center for Research in Epidemiology and Population Health, INSERM Unit 1018, Villejuif, France
19 shared publications - Florent de Vathaire
Center for Research in Epidemiology and Population Health - Unit 1018, Université Paris Saclay, Gustave Roussy, Inserm, UVSQ, EpiRad (Radiation Epidemiology Team), Villejuif, France
19 shared publications - Monia Zidane
Radiation Epidemiology Team, CESP, INSERM U1018 , Villejuif 94800
19 shared publications - Baraah Al Ahmad Nachar
CNRS UMR9019, Gustave Roussy Cancer Campus, Université Paris-Saclay, Equipe Labellisée Ligue Nationale Contre le Cancer Villejuif, France. 2
18 shared publications
Latest Publications
- Open Access
Cancer treatments-related factors for subsequent soft-tissue sarcoma in childhood cancer survivors
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Genetic Risk of Second Malignant Neoplasm after Childhood Cancer Treatment: A Systematic Review
Table S1 displays all the keywords used to search articles in the Pubmed database.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Genetic Risk of Second Malignant Neoplasm after Childhood Cancer Treatment: A Systematic Review
Table S1 displays all the keywords used to search articles in the Pubmed database.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Genetic Risk of Second Malignant Neoplasm after Childhood Cancer Treatment: A Systematic Review
Table S3 displays all the keywords used to search articles in the WOS database.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Genetic Risk of Second Malignant Neoplasm after Childhood Cancer Treatment: A Systematic Review
Table S3 displays all the keywords used to search articles in the WOS database.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Genetic Risk of Second Malignant Neoplasm after Childhood Cancer Treatment: A Systematic Review
Table S4 presents the quality control results using the q-genie scale for each article included in this review.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Genetic Risk of Second Malignant Neoplasm after Childhood Cancer Treatment: A Systematic Review
Table S4 presents the quality control results using the q-genie scale for each article included in this review.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Genetic Risk of Second Malignant Neoplasm after Childhood Cancer Treatment: A Systematic Review
Table S5 summarizes the reasons behind the exclusion of 15 articles following the review of their full texts.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Genetic Risk of Second Malignant Neoplasm after Childhood Cancer Treatment: A Systematic Review
Table S5 summarizes the reasons behind the exclusion of 15 articles following the review of their full texts.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Genetic Risk of Second Malignant Neoplasm after Childhood Cancer Treatment: A Systematic Review
Table S2 displays all the keywords used to search articles in the Scopus database.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Genetic Risk of Second Malignant Neoplasm after Childhood Cancer Treatment: A Systematic Review
Table S2 displays all the keywords used to search articles in the Scopus database.
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Étude de la survenue de maladies cardiaques à long terme après le traitement du cancer dans l'enfance : Identification de marqueurs biologiques associés
Les progrès en oncologie pédiatrique ont conduit à améliorer le pronostic des patients traités pour un cancer de l’enfant ou de l’adolescent avec une survie à 5 ans supérieure à 80%. Cependant, ces patients présentent un risque accru de complications tardives secondaires au traitement du cancer. Les pathologies cardiaques sont une préoccupation majeure au sein de cette population de survivants ayant été exposés à des traitements cardiotoxiques comme les anthracyclines et/ou les radiations au cœur. La capacité des modèles à prédire les pathologies cardiaques à partir de facteurs cliniques et des traitements reste encore insuffisante. Chez des survivants traités de façon similaire, une variabilité interindividuelle de la susceptibilité à la cardiotoxicité a été observée, suggérant l’existence de facteurs génétiques modulant cette susceptibilité. Dans une première partie, nous avons étudié les risques associés aux traitements cardiotoxiques sur la survenue des pathologies cardiaques tardives chez les enfants traités pour un cancer au sein de la cohorte FCCSS. Nous avons mis en évidence le rôle del’irradiation à de faibles volumes cardiaques et la présence d’interaction entre l'irradiation cardiaque et l’administration d’anthracyclines. Dans une deuxième partie, nous avons rapporté à travers une revue systématique de la littérature des facteurs génétiques associés aux pathologies cardiaques chez les survivants d’un cancer dans l’enfance. Dans une troisième partie, une étude cas- témoins appariée nichée dans la cohorte FCCSS a été conduite pour identifier des biomarqueurs du transcriptome associés aux pathologies cardiaques et à l’insuffisance cardiaque en particulier. Le gène NFE2L2 a été identifié avec une expression élevée associée à une diminution du risque de ces évènements. En conclusion, les travaux de cette thèse contribuent à mieux comprendre les facteurs influençant les risques de complications cardiaques tardives chez les enfants traités pour cancer. Nos résultats pourraient être intégrés après validation dans la pratique clinique courante pour l’adaptation de la prise en charge thérapeutique des enfants atteints de cancer et pour les recommandations de leur suivi à long terme.
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Étude de la survenue de maladies cardiaques à long terme après le traitement du cancer dans l'enfance : Identification de marqueurs biologiques associés
Les progrès en oncologie pédiatrique ont conduit à améliorer le pronostic des patients traités pour un cancer de l’enfant ou de l’adolescent avec une survie à 5 ans supérieure à 80%. Cependant, ces patients présentent un risque accru de complications tardives secondaires au traitement du cancer. Les pathologies cardiaques sont une préoccupation majeure au sein de cette population de survivants ayant été exposés à des traitements cardiotoxiques comme les anthracyclines et/ou les radiations au cœur. La capacité des modèles à prédire les pathologies cardiaques à partir de facteurs cliniques et des traitements reste encore insuffisante. Chez des survivants traités de façon similaire, une variabilité interindividuelle de la susceptibilité à la cardiotoxicité a été observée, suggérant l’existence de facteurs génétiques modulant cette susceptibilité. Dans une première partie, nous avons étudié les risques associés aux traitements cardiotoxiques sur la survenue des pathologies cardiaques tardives chez les enfants traités pour un cancer au sein de la cohorte FCCSS. Nous avons mis en évidence le rôle del’irradiation à de faibles volumes cardiaques et la présence d’interaction entre l'irradiation cardiaque et l’administration d’anthracyclines. Dans une deuxième partie, nous avons rapporté à travers une revue systématique de la littérature des facteurs génétiques associés aux pathologies cardiaques chez les survivants d’un cancer dans l’enfance. Dans une troisième partie, une étude cas- témoins appariée nichée dans la cohorte FCCSS a été conduite pour identifier des biomarqueurs du transcriptome associés aux pathologies cardiaques et à l’insuffisance cardiaque en particulier. Le gène NFE2L2 a été identifié avec une expression élevée associée à une diminution du risque de ces évènements. En conclusion, les travaux de cette thèse contribuent à mieux comprendre les facteurs influençant les risques de complications cardiaques tardives chez les enfants traités pour cancer. Nos résultats pourraient être intégrés après validation dans la pratique clinique courante pour l’adaptation de la prise en charge thérapeutique des enfants atteints de cancer et pour les recommandations de leur suivi à long terme.
- Open Access
- 23 September 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (9) , 1066-1080
Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study
Background and Aims: Cardiotoxic treatments like anthracyclines and heart-directed radiotherapy increase the risk of cardiac diseases (CDs) in childhood cancer survivors (CCSs), but individual differences in CD incidence are not fully understood. This study aims to identify transcriptomic biomarkers associated with CD occurrence after childhood cancer treatment. Methods: A matched case-control study was conducted on a sample of 330 CCS: 165 cases with CD and 165 CD-free controls. The expression of 8557 genes was investigated to select those associated with CD and heart failure (HF), using three stabilization approaches derived for the conditional logistic regression with Lasso (Percentile lasso, Bolasso, and Sublasso). The intersection of the three selected gene sets formed the final selection. The interactions between cancer treatment doses and selected genes were investigated. Results: One promising gene, NFE2L2, constituted the final selection, and its expression was lower in cases than in controls [CD: odds ratio (OR) .16, 95% confidence interval (CI) .09–.29; HF: OR .11, 95% CI .03–.37]. No interaction between treatment doses and NFE2L2 expression levels was found in our study. Incorporating NFE2L2 gene expression into prognostic models improved discrimination between cases and controls compared with models based solely on clinical and treatment variables [CD: area under the curve (AUC) .85 vs .66; HF: AUC .87 vs .77]. Conclusions: Using high-dimensional data selection methods has enabled the identification of the gene NFE2L2, associated with CD and HF in CCS. Further research is needed to validate this finding and achieve a better understanding of the biological mechanisms leading to cardiac toxicities and so to develop risk-adapted treatment and surveillance strategies.
- 23 September 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (9) , 1066-1080
Open AccessTranscriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study
Background and Aims: Cardiotoxic treatments like anthracyclines and heart-directed radiotherapy increase the risk of cardiac diseases (CDs) in childhood cancer survivors (CCSs), but individual differences in CD incidence are not fully understood. This study aims to identify transcriptomic biomarkers associated with CD occurrence after childhood cancer treatment. Methods: A matched case-control study was conducted on a sample of 330 CCS: 165 cases with CD and 165 CD-free controls. The expression of 8557 genes was investigated to select those associated with CD and heart failure (HF), using three stabilization approaches derived for the conditional logistic regression with Lasso (Percentile lasso, Bolasso, and Sublasso). The intersection of the three selected gene sets formed the final selection. The interactions between cancer treatment doses and selected genes were investigated. Results: One promising gene, NFE2L2, constituted the final selection, and its expression was lower in cases than in controls [CD: odds ratio (OR) .16, 95% confidence interval (CI) .09–.29; HF: OR .11, 95% CI .03–.37]. No interaction between treatment doses and NFE2L2 expression levels was found in our study. Incorporating NFE2L2 gene expression into prognostic models improved discrimination between cases and controls compared with models based solely on clinical and treatment variables [CD: area under the curve (AUC) .85 vs .66; HF: AUC .87 vs .77]. Conclusions: Using high-dimensional data selection methods has enabled the identification of the gene NFE2L2, associated with CD and HF in CCS. Further research is needed to validate this finding and achieve a better understanding of the biological mechanisms leading to cardiac toxicities and so to develop risk-adapted treatment and surveillance strategies.
- Open Access
- 24 May 2025
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 25 (3) , 1-12
Influence of genetic biomarkers on cardiac diseases in childhood cancer survivors: a systematic review
Childhood cancer survivors (CCS) often suffer from cardiac disease (CD) after treatment that included anthracycline and radiotherapy involving the heart. However, the variability in CD occurrence cannot be explained solely by these treatments, suggesting the existence of genetic predisposition. We conducted a systematic review searching on Medline-PubMed and Scopus, to identify studies reporting associations between genetic factors and CD in CCS. We included studies published up to 11 April 2023, with no lower limit, and assessed the quality of genetic associations by the Q-genie tool. As a result, 20 studies were included (15 case-control and five cohorts), revealing several genes and variants associated with cardiomyopathy, among which, SLC28A3-rs7853758, RARG-rs2229774, P2RX7-rs208294 and P2RX7-rs3751143 variants gave the most consistent findings. This review highlights the necessity to establish a set of clinically useful genes and variants to identify patients most at risk of developing cardiomyopathy, and to implement monitoring and prevention strategies.
- 24 May 2025
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 25 (3) , 1-12
Open AccessInfluence of genetic biomarkers on cardiac diseases in childhood cancer survivors: a systematic review
Childhood cancer survivors (CCS) often suffer from cardiac disease (CD) after treatment that included anthracycline and radiotherapy involving the heart. However, the variability in CD occurrence cannot be explained solely by these treatments, suggesting the existence of genetic predisposition. We conducted a systematic review searching on Medline-PubMed and Scopus, to identify studies reporting associations between genetic factors and CD in CCS. We included studies published up to 11 April 2023, with no lower limit, and assessed the quality of genetic associations by the Q-genie tool. As a result, 20 studies were included (15 case-control and five cohorts), revealing several genes and variants associated with cardiomyopathy, among which, SLC28A3-rs7853758, RARG-rs2229774, P2RX7-rs208294 and P2RX7-rs3751143 variants gave the most consistent findings. This review highlights the necessity to establish a set of clinically useful genes and variants to identify patients most at risk of developing cardiomyopathy, and to implement monitoring and prevention strategies.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Table S4 from Genetic Risk of Second Malignant Neoplasm after Childhood Cancer Treatment: A Systematic Review
Table S4 presents the quality control results using the q-genie scale for each article included in this review.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Genetic Risk of Second Malignant Neoplasm after Childhood Cancer Treatment: A Systematic Review
Table S4 presents the quality control results using the q-genie scale for each article included in this review.